Search
SOLACI Congress
International CongressesESC 2019

ESC 2019

solaci
solaci
92
0

Here you will find the highlights of the ESC 2019 Congres, held on August 31st to September 4th in Paris, France.

If you cannot view the articles, click here

Previous article
ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.
Next article
Experts Reach Consensus on Post TAVR Pacemaker Indication
solaci
solaci

More articles by this author

EuroPCR 2024

solaci - 0
Here are the most important scientific articles of the EuroPCR 2024 Scientific Sessions. If you cannot view the articles, click here

ACC 2024

solaci - 0
Here are the most important scientific articles of the ACC 2024 Scientific Sessions. If you cannot view the articles, click here

AHA 2023

solaci - 0
Here are the most important scientific articles of the AHA 2023 Congress. If you cannot view the articles, click here

TCT 2023

solaci - 0
Here are the most important scientific articles of the TCT 2023 Congress. If you cannot view the articles, click here

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

EuroPCR 2024

EuroPCR 2024

Here are the most important scientific articles of the EuroPCR 2024 Scientific Sessions. If you cannot view the articles, click here
solaci -
SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

Dr. Carlos Fava - 0
One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TAVR in Small Annuli: What Valve Should We Use?

Dr. Carlos Fava - 0
One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

Institutional News

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy